Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,485 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,566 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04535713 | GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma | unknown | Phase 2 | 260 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT03079323 | Trial to Investigate the Benefit of Elective Para-Aortic Radiotherapy (PART) for pN1 Prostate Cancer(PART) | unknown | Phase 2 | 137 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jul 3, 2024 |
| clinicaltrials |
| NCT03080116 | Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy(ARNEO) | unknown | Phase 2 | 90 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT03340376 | Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer | unknown | Phase 2 | 48 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT03784066 | Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity(DUTRELASCO) | unknown | Phase 1 / Phase 2 | 21 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT04562337 | SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC | unknown | Phase 2 | 67 | Shandong Cancer Hospital and InstituteOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT05229003 | Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC | unknown | Phase 2 | 44 | Fudan UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06090656 | Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria)(BEST) | unknown | Phase 2 | 88 | Sun Yat-sen UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06484361 | PET/MRI to Stage Prostate Cancer Patients | unknown | Phase 2 | 50 | IRCCS San RaffaeleOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06485713 | Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib for Third-line Treatment of mCRC | unknown | Phase 2 | 200 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT02628405 | R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma | unknown | Phase 1 / Phase 2 | 30 | Academic and Community Cancer Research UnitedOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT06482008 | HAIC Combined With Adebrelimab Plus Apatinib as the First-line Treatment for HCC in BCLC Stage C: An Open-label, Single-arm, Phase II Study | unknown | Phase 2 | 33 | Sun Yat-sen UniversityOTHER | 0 | Jul 1, 2024 | clinicaltrials |
| NCT06479759 | LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung Cancer(ACCLAIM) | unknown | Phase 2 | 50 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT04778579 | Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy(CART19-BE-02) | unknown | Phase 2 | 50 | Sara V. LatorreOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06475287 | HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 42 | Fudan UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06475417 | Neoadjuvant Adebrelimab + DOS in Locally Advanced Resectable Gastric Cancer | unknown | Phase 2 | 42 | Tang-Du HospitalOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06311695 | Contrast-Enhanced Spectral Mammography (CESM)(CESM) | unknown | Phase 2 | 263 | European Institute of OncologyOTHER | 1 | Jun 24, 2024 | clinicaltrials |
| NCT03293173 | Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis(Bio-CHIC) | unknown | Phase 2 | 120 | Nordic Lymphoma GroupNETWORK | 4 | Jun 21, 2024 | clinicaltrials |
| NCT03942224 | Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma(DeRIVE) | unknown | Phase 2 | 49 | Emory UniversityOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT05060432 | Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors(TIG-006) | unknown | Phase 1 / Phase 2 | 153 | iTeos Belgium SAINDUSTRY | 6 | Jun 21, 2024 | clinicaltrials |
| NCT05444088 | Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 129 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 21, 2024 | clinicaltrials |
| NCT06467565 | NALIRIFOX as Induction Therapy in LAPC | unknown | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT06468254 | An Exploratory Clinical Study of Statins for Improving Chemotherapy and Maintenance in Patients With Ovarian Cancer | unknown | Phase 2 | 500 | Anhui Provincial Cancer HospitalOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT06464614 | Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC. | unknown | Phase 2 | 54 | The First Affiliated Hospital of Henan University of Science and TechnologyOTHER | 1 | Jun 18, 2024 | clinicaltrials |
| NCT05422027 | Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma | unknown | Phase 1 / Phase 2 | 42 | Xia ZhongjunOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT05422066 | Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma | unknown | Phase 2 | 50 | Li ZhimingOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT05816499 | Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)(AK104IIT018) | unknown | Phase 1 / Phase 2 | 50 | Shanghai Chest HospitalOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT06463171 | Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer | unknown | Phase 2 | 60 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT03867799 | iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer | unknown | Phase 2 | 25 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT05766748 | Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 30 | Cantex PharmaceuticalsINDUSTRY | 1 | Jun 14, 2024 | clinicaltrials |
| NCT05832892 | Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 41 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT06372626 | Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma. | unknown | Phase 1 / Phase 2 | 93 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jun 14, 2024 | clinicaltrials |
| NCT02042807 | To Evaluate the Effect of MCS® in Prostate Cancer Prevention(MCS-8) | unknown | Phase 2 | 702 | Health Ever Bio-Tech Co., Ltd.INDUSTRY | 1 | Jun 13, 2024 | clinicaltrials |
| NCT04818333 | A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 157 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 13, 2024 | clinicaltrials |
| NCT06455072 | Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer | unknown | Phase 2 | 37 | Fujian Cancer HospitalOTHER_GOV | 1 | Jun 12, 2024 | clinicaltrials |
| NCT04215003 | A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC | unknown | Phase 1 / Phase 2 | 20 | Fudan UniversityOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT06018896 | Vitamin C to Quality of Life in Patients With Terminal Stage Pancreatic Cancer(PTCA199-4) | unknown | Phase 2 | 20 | Fudan UniversityOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT05638451 | Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients | unknown | Phase 2 | 30 | Zhujiang HospitalOTHER | 1 | Jun 5, 2024 | clinicaltrials |
| NCT06313541 | Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy | unknown | Phase 2 | 146 | Fudan UniversityOTHER | 1 | Jun 5, 2024 | clinicaltrials |
| NCT02061800 | CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant | unknown | Phase 1 / Phase 2 | 14 | Diane GeorgeOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT04322578 | Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC(CONFIRM) | unknown | Phase 2 | 120 | Hunan Province Tumor HospitalOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05304234 | Liver Cancer Disparities in American Indian and Alaska Native Persons | unknown | Phase 2 | 200 | University of WashingtonOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT02993198 | A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging | unknown | Phase 2 | 134 | Northwestern UniversityOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT06436976 | The Effect of Probiotics ATG-F4 in Cancer Patients | unknown | Phase 2 | 30 | Chungnam National University HospitalOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT06437678 | Phase II Study of Liposomal Irinotecan for Advanced Refractory Gastric Cancer | unknown | Phase 2 | 50 | Zhejiang Cancer HospitalOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT06434090 | Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 74 | Sun Yat-sen UniversityOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT03714490 | MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy for Unresectable Rectal Cancer(SUNRISE) | unknown | Phase 2 | 200 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT03921671 | Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)(RELEVENT) | unknown | Phase 2 | 60 | Claudia ProtoOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT05493800 | Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT(Capella) | unknown | Phase 2 | 60 | MitoImmune TherapeuticsINDUSTRY | 1 | May 29, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Jul 5, 2024source: clinicaltrials